Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 61

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Diffuse large B-cell lymphoma refractory+2

Recruiting

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Study of Atezolizumab, Paclitaxel, and Carboplatin for Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion GECP

Biliary cancer metastatic

Recruiting

Study Comparing Ivonescimab to FOLFOX Drug Combination for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Unicancer

Colorectal cancer

Recruiting

Study on Avelumab and Cetuximab for Patients with Metastatic Colorectal Cancer Who Have Previously Received Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Cancer fatigue

Recruiting

Study on Methylphenidate for Reducing Fatigue in Childhood Brain Tumor Survivors

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:METHYLPHENIDATE
  • Sponsor:Odense University Hospital

Colon cancer

Recruiting

Study on the Effectiveness of Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine for Patients with Locally Advanced Colon Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Clinica Universidad De Navarra

Study of FG001 for Detecting Meningioma or Low-Grade Glioma in Patients Undergoing Neurosurgery

Recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:FG001
  • Sponsor:Copenhagen University Hospital

Squamous cell carcinoma of skin

Recruiting

Study of nivolumab and ipilimumab combination therapy as an alternative to surgery and radiation in patients with skin squamous cell carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Prostate cancer metastatic

Recruiting

Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:177LU-PSMA-I&T
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Neoplasm malignant

Recruiting

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Chronic lymphocytic leukaemia+2

Recruiting

Study of IDP-121 for Patients with Relapsed or Refractory Multiple Myeloma, B-cell Lymphoma, or Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IDP-121
  • Sponsor:Idp Discovery Pharma S.L.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.